BioCentury
ARTICLE | Company News

Cancer Prevention Pharmaceuticals, Zeria deal

January 13, 2014 8:00 AM UTC

Cancer Prevention granted Zeria's Tillotts Pharma AG subsidiary exclusive rights to develop and commercialize CPP-1X/sulindac in Europe and Japan to treat familial adenomatous polyposis (FAP). Cancer Prevention is eligible to receive over $100 million in upfront and development and regulatory milestone payments, plus royalties escalating to double digits. The deal may be expanded to include additional indications. Cancer Prevention will be responsible for development, and Tillotts will be responsible for obtaining regulatory approval and commercialization in the territories. Zeria will be responsible for development and commercialization in Japan. FAP is an Orphan disease characterized by the development of multiple benign polyps in the colon that can become cancerous if left untreated. ...